Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

123I-MIBG SPECT/CT for Assessment of Cardiac Sympathetic Innervation

This study has been completed.
Information provided by:
Rambam Health Care Campus Identifier:
First received: February 24, 2006
Last updated: August 17, 2011
Last verified: August 2011
Myocardial scintigraphy with 123I-MIBG allows for visual and semi-quantitative assessment of sympathetic cardiac innervation using the hear to mediastinum ratio (HMR). Impaired cardiac MIBG clearance may occur in patients with congestive heart failure (CHF). The purpose of present study was to develop and validate a quantitative index for the assessment of cardiac MIBG uptake kinetics using SPECT/CT for diagnosis of CHF

Condition Intervention Phase
Cardiac Diseases
Device: SPECT/CT
Phase 0

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Quantitative 123I-MIBG SPECT/CT Assessment of Cardiac Sympathetic Innervation

Further study details as provided by Rambam Health Care Campus:

Primary Outcome Measures:
  • The impact of the imaging modality on patient management [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The impact on patient management [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Enrollment: 50
Study Start Date: May 2007
Study Completion Date: May 2010
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: SPECT/CT

Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients refered for neuroendocrine diseases

Inclusion Criteria:

  • age>40

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00296738

Rambam Medical Center
Haifa, Israel
Sponsors and Collaborators
Rambam Health Care Campus
Principal Investigator: Shmuel Rispler, MD PhD Rambam Health Care Campus
  More Information

Responsible Party: Dr. Alex Frenkel, Rambam Medical Center Identifier: NCT00296738     History of Changes
Other Study ID Numbers: MIBGCTIL 
Study First Received: February 24, 2006
Last Updated: August 17, 2011
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:
Heart Diseases
Cardiovascular Diseases processed this record on October 21, 2016